Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

Impact of Salinomycin on human cholangiocarcinoma: induction of apoptosis and impairment of tumor cell proliferation in vitro

Authors: Thorsten Lieke, Wolf Ramackers, Sabine Bergmann, Jürgen Klempnauer, Michael Winkler, Johannes Klose

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

Cholangiocarcinoma (CC) is a primary liver cancer with increasing incidence worldwide. Despite all efforts made in past years, prognosis remains to be poor. At least in part, this might be explained by a pronounced resistance of CC cells to undergo apoptosis. Thus, new therapeutic strategies are imperatively required. In this study we investigated the effect of Salinomycin, a polyether ionophore antibiotic, on CC cells as an appropriate agent to treat CC. Salinomycin was quite recently identified to induce apoptosis in cancer stem cells and to overcome apoptosis-resistance in several leukemia-cells and other cancer cell lines of different origin.

Methods

To delineate the effects of Salinomycin on CC, we established an in vitro cell culture model using three different human CC cell lines. After treatment apoptosis as well as migration and proliferation behavior was assessed and additional cell cycle analyses were performed by flowcytometry.

Results

By demonstrating Annexin V and TUNEL positivity of human CC cells, we provide evidence that Salinomycin reveals the capacity to break apoptosis-resistance in CC cells. Furthermore, we are able to demonstrate that the non-apoptotic cell fraction is characterized by sustainable impaired migration and proliferation. Cell cycle analyses revealed G2-phase accumulation of human CC cells after treatment with Salinomycin. Even though apoptosis is induced in two of three cell lines of CC cells, one cell line remained unaffected in regard of apoptosis but revealed as the other CC cells decreased proliferation and migration.

Conclusion

In this study, we are able to demonstrate that Salinomycin is an effective agent against previously resistant CC cells and might be a potential candidate for the treatment of CC in the future.
Appendix
Available only for authorised users
Literature
1.
Lazaridis KN, Gores GJ: Cholangiocarcinoma. Gastroenterology. 2005, 128 (6): 1655-1667. 10.1053/j.gastro.2005.03.040.CrossRefPubMed
2.
Shaib Y, El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004, 24 (2): 115-125. 10.1055/s-2004-828889.CrossRefPubMed
3.
Welzel TM, McGlynn KA, Hsing AW, O'Brien TR, Pfeiffer RM: Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst. 2006, 98 (12): 873-875. 10.1093/jnci/djj234.CrossRefPubMed
4.
5.
Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ, Youssef BM, Klimstra D, Blumgart LH: Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg. 2001, 234 (4): 507-517. 10.1097/00000658-200110000-00010. discussion 517–509CrossRefPubMedPubMedCentral
6.
Rea DJ, Rosen CB, Nagorney DM, Heimbach JK, Gores GJ: Transplantation for cholangiocarcinoma: when and for whom?. Surg Oncol Clin N Am. 2009, 18 (2): 325-337. 10.1016/j.soc.2008.12.008. ixCrossRefPubMed
7.
Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010, 362 (14): 1273-1281. 10.1056/NEJMoa0908721.CrossRefPubMed
8.
Wise C, Pilanthananond M, Perry BF, Alpini G, McNeal M, Glaser SS: Mechanisms of biliary carcinogenesis and growth. World J Gastroenterol. 2008, 14 (19): 2986-2989. 10.3748/wjg.14.2986.CrossRefPubMedPubMedCentral
9.
Miyazaki Y, Shibuya M, Sugawara H, Kawaguchi O, Hirsoe C: Salinomycin, a new polyether antibiotic. J Antibiot (Tokyo). 1974, 27 (11): 814-821. 10.7164/antibiotics.27.814.CrossRef
10.
Mitani M, Yamanishi T, Miyazaki Y: Salinomycin: a new monovalent cation ionophore. Biochem Biophys Res Commun. 1975, 66 (4): 1231-1236. 10.1016/0006-291X(75)90490-8.CrossRefPubMed
11.
Mitani M, Yamanishi T, Miyazaki Y, Otake N: Salinomycin effects on mitochondrial ion translocation and respiration. Antimicrob Agents Chemother. 1976, 9 (4): 655-660. 10.1128/AAC.9.4.655.CrossRefPubMedPubMedCentral
12.
Daugschies A, Gasslein U, Rommel M: Comparative efficacy of anticoccidials under the conditions of commercial broiler production and in battery trials. Vet Parasitol. 1998, 76 (3): 163-171. 10.1016/S0304-4017(97)00203-3.CrossRefPubMed
13.
Callaway TR, Edrington TS, Rychlik JL, Genovese KJ, Poole TL, Jung YS, Bischoff KM, Anderson RC, Nisbet DJ: Ionophores: their use as ruminant growth promotants and impact on food safety. Curr Issues Intest Microbiol. 2003, 4 (2): 43-51.PubMed
14.
Lindemann MD, Kornegay ET, Stahly TS, Cromwell GL, Easter RA, Kerr BJ, Lucas DM: The efficacy of salinomycin as a growth promotant for swine from 9 to 97 kg. J Anim Sci. 1985, 61 (4): 782-788.PubMed
15.
Naujokat C, Fuchs D, Opelz G: Salinomycin in cancer: A new mission for an old agent. Mol Med Report. 2010, 3 (4): 555-559.CrossRef
16.
Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES: Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009, 138 (4): 645-659. 10.1016/j.cell.2009.06.034.CrossRefPubMedPubMedCentral
17.
Kim JH, Chae M, Kim WK, Kim YJ, Kang HS, Kim HS, Yoon S: Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein. Br J Pharmacol. 2011, 162 (3): 773-784. 10.1111/j.1476-5381.2010.01089.x.CrossRefPubMedPubMedCentral
18.
Dong TT, Zhou HM, Wang LL, Feng B, Lv B, Zheng MH: Salinomycin selectively targets 'CD133+' cell subpopulations and decreases malignant traits in colorectal cancer lines. Ann Surg Oncol. 2011, 18 (6): 1797-1804. 10.1245/s10434-011-1561-2.CrossRefPubMed
19.
Fuchs D, Daniel V, Sadeghi M, Opelz G, Naujokat C: Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun. 2010, 394 (4): 1098-1104. 10.1016/j.bbrc.2010.03.138.CrossRefPubMed
20.
Fuchs D, Heinold A, Opelz G, Daniel V, Naujokat C: Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem Biophys Res Commun. 2009, 390 (3): 743-749. 10.1016/j.bbrc.2009.10.042.CrossRefPubMed
21.
Saijyo S, Kudo T, Suzuki M, Katayose Y, Shinoda M, Muto T, Fukuhara K, Suzuki T, Matsuno S: Establishment of a new extrahepatic bile duct carcinoma cell line, TFK-1. Tohoku J Exp Med. 1995, 177 (1): 61-71. 10.1620/tjem.177.61.CrossRefPubMed
22.
Knuth A, Gabbert H, Dippold W, Klein O, Sachsse W, Bitter-Suermann D, Prellwitz W, Buschenfelde KH Mz: Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J Hepatol. 1985, 1 (6): 579-596. 10.1016/S0168-8278(85)80002-7.CrossRefPubMed
23.
International Conference on Tumor Necrosis Factor and Related Cytotoxins: September 14–18, 1987, Heidelberg, Federal Republic of Germany. Abstracts. Immunobiology. 1987, 175 (1–2): 1-143.
24.
Ishimura N, Isomoto H, Bronk SF, Gores GJ: Trail induces cell migration and invasion in apoptosis-resistant cholangiocarcinoma cells. Am J Physiol Gastrointest Liver Physiol. 2006, 290 (1): G129-136.CrossRefPubMed
25.
Fingas CD, Blechacz BR, Smoot RL, Guicciardi ME, Mott J, Bronk SF, Werneburg NW, Sirica AE, Gores GJ: A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells. Hepatology. 2010, 52 (2): 550-561. 10.1002/hep.23729.CrossRefPubMedPubMedCentral
26.
Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD: Cholangiocarcinoma. Lancet. 2005, 366 (9493): 1303-1314. 10.1016/S0140-6736(05)67530-7.CrossRefPubMed
27.
Baradari V, Hopfner M, Huether A, Schuppan D, Scherubl H: Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. World J Gastroenterol. 2007, 13 (33): 4458-4466.CrossRefPubMedPubMedCentral
28.
Fingas CD, Mertens JC, Razumilava N, Bronk SF, Sirica AE, Gores GJ: Targeting PDGFR-beta in Cholangiocarcinoma. Liver Int. 2012, 32 (3): 400-409.PubMed
29.
Takayama Y, Kokuryo T, Yokoyama Y, Ito S, Nagino M, Hamaguchi M, Senga T: Silencing of Tousled-like kinase 1 sensitizes cholangiocarcinoma cells to cisplatin-induced apoptosis. Cancer Lett. 2010, 296 (1): 27-34. 10.1016/j.canlet.2010.03.011.CrossRefPubMed
30.
Yun BR, Lee MJ, Kim JH, Kim IH, Yu GR, Kim DG: Enhancement of parthenolide-induced apoptosis by a PKC-alpha inhibition through heme oxygenase-1 blockage in cholangiocarcinoma cells. Exp Mol Med. 2010, 42 (11): 787-797. 10.3858/emm.2010.42.11.082.CrossRefPubMedPubMedCentral
31.
Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA: Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011, 108 (32): 13253-13257. 10.1073/pnas.1110431108.CrossRefPubMedPubMedCentral
32.
Ketola K, Hilvo M, Hyotylainen T, Vuoristo A, Ruskeepaa AL, Oresic M, Kallioniemi O, Iljin K: Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. Br J Cancer. 2012, 106 (1): 99-106. 10.1038/bjc.2011.530.CrossRefPubMedPubMedCentral
33.
34.
Salvesen GS: Caspases: opening the boxes and interpreting the arrows. Cell Death Differ. 2002, 9 (1): 3-5. 10.1038/sj.cdd.4400963.CrossRefPubMed
35.
Wang Z, Tang X, Zhang Y, Qi R, Li Z, Zhang K, Liu Z, Yang X: Lobaplatin induces apoptosis and arrests cell cycle progression in human cholangiocarcinoma cell line RBE. Biomed Pharmacother. 2012, 66 (3): 161-166. 10.1016/j.biopha.2011.09.008.CrossRefPubMed
36.
Liu CC, Prior J, Piwnica-Worms D, Bu G: LRP6 overexpression defines a class of breast cancer subtype and is a target for therapy. Proc Natl Acad Sci U S A. 2010, 107 (11): 5136-5141. 10.1073/pnas.0911220107.CrossRefPubMedPubMedCentral
37.
Tokumoto N, Ikeda S, Ishizaki Y, Kurihara T, Ozaki S, Iseki M, Shimizu Y, Itamoto T, Arihiro K, Okajima M, et al: Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas. Int J Oncol. 2005, 27 (4): 973-980.PubMed
38.
Wachter J, Neureiter D, Alinger B, Pichler M, Fuereder J, Oberdanner C, Di Fazio P, Ocker M, Berr F, Kiesslich T: Influence of five potential anticancer drugs on wnt pathway and cell survival in human biliary tract cancer cells. Int J Biol Sci. 2012, 8 (1): 15-29.CrossRefPubMed
39.
Kim KY, Yu SN, Lee SY, Chun SS, Choi YL, Park YM, Song CS, Chatterjee B, Ahn SC: Salinomycin-induced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization. Biochem Biophys Res Commun. 2011, 413 (1): 80-86. 10.1016/j.bbrc.2011.08.054.CrossRefPubMed
40.
Kim JH, Yoo HI, Kang HS, Ro J, Yoon S: Salinomycin sensitizes antimitotic drugs-treated cancer cells by increasing apoptosis via the prevention of G2 arrest. Biochem Biophys Res Commun. 2012, 418 (1): 98-103. 10.1016/j.bbrc.2011.12.141.CrossRefPubMed
41.
Kim WK, Kim JH, Yoon K, Kim S, Ro J, Kang HS, Yoon S: Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest. Invest New Drugs. 2012, 30 (4): 1311-1318. 10.1007/s10637-011-9685-6.CrossRefPubMed
42.
Story P, Doube A: A case of human poisoning by salinomycin, an agricultural antibiotic. N Z Med J. 2004, 117 (1190): U799-PubMed
43.
Plumlee KH, Johnson B, Galey FD: Acute salinomycin toxicosis of pigs. J Vet Diagn Invest. 1995, 7 (3): 419-420. 10.1177/104063879500700327.CrossRefPubMed
44.
Kosal ME, Anderson DE: An unaddressed issue of agricultural terrorism: a case study on feed security. J Anim Sci. 2004, 82 (11): 3394-3400.PubMed
Metadata
Title
Impact of Salinomycin on human cholangiocarcinoma: induction of apoptosis and impairment of tumor cell proliferation in vitro
Authors
Thorsten Lieke
Wolf Ramackers
Sabine Bergmann
Jürgen Klempnauer
Michael Winkler
Johannes Klose
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-466

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue

Research article

A systems biology approach to the global analysis of transcription factors in colorectal cancer

Research article

Involvement of Akt/NF-κB pathway in antitumor effects of parthenolide on glioblastoma cells in vitro and in vivo

Research article

SDHA loss of function mutations in a subset of young adult wild-type gastrointestinal stromal tumors

Research article

miRNA-135a promotes breast cancer cell migration and invasion by targeting HOXA10

Research article

Adeno-associated virus-mediated doxycycline-regulatable TRAIL expression suppresses growth of human breast carcinoma in nude mice

Case report

Unilateral follicular variant of papillary thyroid carcinoma with unique KRAS mutation in struma ovarii in bilateral ovarian teratoma: a rare case report
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits